Reviewing Werewolf Therapeutics (NASDAQ:HOWL) and Yarrow Bioscience (NASDAQ:YARW)

Yarrow Bioscience (NASDAQ:YARW) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Analyst Ratings

This is a breakdown of current ratings and price targets for Yarrow Bioscience and Werewolf Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1	0	2	0	2.33
Werewolf Therapeutics	1	4	2	0	2.14

Yarrow Bioscience currently has a consensus target price of $58.00, indicating a potential upside of 157.55%. Werewolf Therapeutics has a consensus target price of $4.00, indicating a potential upside of 333.70%. Given Werewolf Therapeutics’ higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than Yarrow Bioscience.

Insider & Institutional Ownership

83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Yarrow Bioscience and Werewolf Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570,000.00	105.49	-$26.48 million	($14.64)	-1.54
Werewolf Therapeutics	$1.88 million	23.84	-$60.82 million	($0.76)	-1.21

Yarrow Bioscience has higher earnings, but lower revenue than Werewolf Therapeutics. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Yarrow Bioscience has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Profitability

This table compares Yarrow Bioscience and Werewolf Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
Werewolf Therapeutics	N/A	-166.99%	-59.88%

Summary

Werewolf Therapeutics beats Yarrow Bioscience on 7 of the 13 factors compared between the two stocks.

About Yarrow Bioscience

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.